The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Next-generation KRAS inhibitors at ESMO 2026: FMC-376 and INCB161734
Valentina Boni, MD, PhD, Universitary Hospital Quirónsalud Madrid, Madrid, Spain, discusses the emergence of new KRAS inhibitors, including next-generation agents with dual inhibition of KRAS on and off states, which aim to improve efficacy and overcome resistance. Novel agents that were notable included FMC-376, a KRAS G12C ON+OFF inhibitor assessed in a Phase I trial (NCT06244771), and INCB161734, a KRAS G12D inhibitor assessed with cetuximab in heavily pre-treated patients with colorectal cancer in a Phase I trial (NCT06179160). This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
